

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/477,147	06/07/95	LIVINGSTON	P 43016-D/JPW/

HM12/0117

JOHN P WHITE  
COOPER & DUNHAM  
1185 AVENUE OF THE AMERICAS  
NEW YORK NY 10036

EXAMINER

DUFFY, P

ART UNIT	PAPER NUMBER
1645	22

DATE MAILED: 01/17/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08477,147			

EXAMINER	
ART UNIT	PAPER NUMBER
1645	22

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. The proposed reply filed on 10-16-00 is not responsive to the prior Office action because of the following omission(s) or matter(s): the amendment to the claims constitutes a change of invention for the following reasons. The previous claims were examined in light of applicants amendment to recite an oligosaccharide portion of a ganglioside conjugated through a ceramide-derived carbon thus requiring a portion of the ganglioside to be present. The previous claims were considered in light of this specific linkage and the presence of the ganglioside. The now claimed invention does not require that any part of the ceramide portion of the ganglioside or the ganglioside to be present and has apparently changed the linkage. The presently claimed invention, provided by applicants amendment does not reflect gangliosides or linkage through ceramide-derived carbons. Since, Applicants have already received an action on the merits for a different claimed invention (linking the oligosaccharide portion of a ganglioside conjugated through a ceramide-derived carbon), the amended claims drawn to any oligosaccharide conjugated to Keyhole Limpet Hemocyanin constitutes a change of invention. Such changes in invention are not permissible mid-prosecution.

Since the above mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

2. Any inquiry of a general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1604 is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A. Duffy, Ph.D. whose telephone number is (703) 305-7555. The examiner can normally be reached on Monday-Friday from 6:30 AM to 3:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (703) 308-3995.

Patricia A. Duffy, Ph.D.  
January 12, 2001

*Patricia A. Duffy*  
Patricia A. Duffy, Ph.D.  
Primary Examiner  
Group 1600